Literature DB >> 1551312

The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes.

C F Sum1, J M Webster, A B Johnson, C Catalano, B G Cooper, R Taylor.   

Abstract

A stepped intravenous metformin infusion was used in conjunction with the hyperglycaemic clamp technique to study the dose-response relationship of plasma metformin concentration with hepatic glucose production and peripheral glucose disposal in nine patients with Type 2 diabetes. The study was of double-blind crossover design, using NaCl infusion as control. Plasma metformin concentrations spanning the therapeutic range (1.64 +/- 0.13 mg l-1 and 6.57 +/- 0.61 mg l-1) were achieved. No differences in peripheral glucose disposal were demonstrated when compared with NaCl infusion (3.4 +/- 0.1 vs 3.6 +/- 0.2 (+/- SE) mg kg-1 min-1 and 3.4 +/- 0.2 vs 3.3 +/- 0.2 mg kg-1 min-1, respectively). There was also no difference in basal hepatic glucose production during metformin and NaCl infusion (2.7 +/- 0.3 vs 2.8 +/- 0.2 mg kg-1 min-1). No acute effect of metformin on hepatic glucose production or peripheral glucose disposal was observed, implying that a chronic persistent effect is more important in these respects than immediate effects consequent upon changes in plasma drug level.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551312     DOI: 10.1111/j.1464-5491.1992.tb01716.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  38 in total

1.  Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Authors:  Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  JCI Insight       Date:  2018-12-06

2.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Authors:  Marc Foretz; Sophie Hébrard; Jocelyne Leclerc; Elham Zarrinpashneh; Maud Soty; Gilles Mithieux; Kei Sakamoto; Fabrizio Andreelli; Benoit Viollet
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

Review 3.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

4.  Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Authors:  Pei Zhu; Meghan Davis; Amanda J Blackwelder; Nora Bachman; Bolin Liu; Susan Edgerton; Leonard L Williams; Ann D Thor; Xiaohe Yang
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-09

5.  Role of AMP-activated protein kinase in mechanism of metformin action.

Authors:  G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling.

Authors:  Altaf Mohammed; Naveena B Janakiram; Misty Brewer; Rebekah L Ritchie; Anuj Marya; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

7.  Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.

Authors:  James Sinnett-Smith; Krisztina Kisfalvi; Robert Kui; Enrique Rozengurt
Journal:  Biochem Biophys Res Commun       Date:  2012-11-15       Impact factor: 3.575

Review 8.  Therapeutic Concentrations of Metformin: A Systematic Review.

Authors:  Farshad Kajbaf; Marc E De Broe; Jean-Daniel Lalau
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

Review 9.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.

Authors:  C J Dunn; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 10.  An update on mode of action of metformin in modulation of meta-inflammation and inflammaging.

Authors:  Meysam Khodadadi; Davoud Jafari-Gharabaghlou; Nosratollah Zarghami
Journal:  Pharmacol Rep       Date:  2022-01-24       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.